Natco Pharma has received regulatory approval from the Central Drugs Standard Control Organisation (CDSCO) for semaglutide in India, marking a significant milestone in the company's pharmaceutical portfolio expansion. The company has now provided additional clarification regarding its partnership strategy following exchange queries.

Regulatory Approval and Product Details

The CDSCO approval, received on February 14, 2026, enables Natco Pharma to manufacture and distribute semaglutide in the Indian market. Semaglutide is a medication used for managing diabetes and weight management, representing an important addition to the company's therapeutic offerings.

Partnership Strategy and Launch Timeline

In a clarification to BSE Limited dated February 25, 2026, Natco Pharma confirmed its collaboration approach for the semaglutide launch. The company stated it is working with different marketing partners to launch the product in March 2026 in India.

Eris Lifesciences Partnership Details

The company specifically mentioned its partnership with Eris Lifesciences Ltd for the semaglutide product. According to the BSE clarification, this partnership is in the ordinary course of business and has no material impact on the company's operations.

Financial and Operational Impact

Natco Pharma has consistently stated that the semaglutide launch will not significantly affect its operations or financial performance. In the recent clarification, the company reiterated that there is no material financial impact from the partnership or product launch activities.

Regulatory Compliance

The company emphasized its commitment to regulatory compliance, stating it has been consistently making disclosures to stock exchanges as required under Regulation 30 of the SEBI (LODR) Regulations, 2015. The clarification was signed by Ch. Venkat Ramesh, Company Secretary & Compliance Officer, confirming the company's adherence to disclosure requirements.

Natco Pharma Limited has issued a clarification to BSE Limited regarding the recent increase in trading volumes of its shares, attributing the surge to market-driven factors. The pharmaceutical company's response, dated February 25, 2026, addresses BSE's inquiry under reference L/SURV/ONL/PV/SG/2025-2026/935.

Regulatory Compliance and Disclosure

The company emphasized its adherence to regulatory requirements in its communication to the stock exchange. Key aspects of the clarification include:

Volume Movement Explanation

Natco Pharma stated that the increased trading volume in its shares is purely market-driven and results from prevailing market conditions. The company clarified that it has not withheld any material or price-sensitive information that could influence the volume behavior of its shares.

Corporate Communication Details

The clarification letter was signed by Ch. Venkat Ramesh, Company Secretary and Compliance Officer, on February 25, 2026. The response confirms that all disclosures pursuant to Regulation 30 of SEBI (LODR) Regulations, 2015, have been made, covering information that bears on the company's operations and performance.

Regulatory Framework

The communication falls under the standard regulatory framework where stock exchanges monitor unusual price or volume movements and seek clarifications from listed companies. Natco Pharma's response demonstrates its commitment to transparency and regulatory compliance in addressing market inquiries.